Semaglutide as an Adjunct to Dieting in the Treatment of Type 2 Diabetes

Last updated: March 17, 2022
Sponsor: Kirsi Pietiläinen
Overall Status: Active - Recruiting

Phase

4

Condition

Diabetes Mellitus, Type 2

Diabetes And Hypertension

Diabetes Prevention

Treatment

N/A

Clinical Study ID

NCT04854083
2020
  • Ages 18-65
  • All Genders

Study Summary

The pharmacological approaches in the treatment of type 2 diabetes (T2DM) have advanced radically during the last decades. However, focus on long-term management of body weight, which is an essential part of treatment success, is often lacking. Excluding surgery, there are only a few effective treatment methods for obesity. Management of obesity is also greatly challenged by weight regain, which is common after a successful lifestyle intervention. Weight regain typically results in the deterioration of glucose homeostasis in T2DM. However, understanding the pathomechanisms of weight regain and subsequent worsening of glucose homeostasis is still insufficient. Therefore, T2DM treatment programs that target long-term weight management have been scarce. This study aims to fill the gaps in the current knowledge by advancing the development of treatment programs for T2DM that simultaneously head for improved glucose metabolism and improved long-term body weight control.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥18 years and <65 years
  • BMI: ≥27 kg/m2
  • T2DM (HbA1c ≥ 6.0% if on anti-diabetic medication or HbA1c≥6.5% if non- medicated)
  • Participant is willing and able to give informed consent for participation in thestudy

Exclusion

Exclusion Criteria:

  • Contraindication to trial drugs
  • Use of insulin or GLP-1RAs (during the past 3 months)
  • Use of anti-obesity drugs (during the past 3 months)
  • Weight change of >5% during the past 3 months
  • Bariatric surgery or planned bariatric surgery during the trial
  • History of pancreatitis
  • Impaired renal function (GFR<30 ml/min/1.73m2)
  • Impaired hepatic function (ALAT>2 x upper limit normal)
  • Clinically significant active cardiovascular disease
  • Clinically significant abnormality in the ECG
  • Cancer (except basal or squamous cell skin cancers)
  • Major psychiatric disease (such as severe depression, bipolar disorder, schizophrenia)
  • Substance abuse
  • Learning disability
  • Females of childbearing potential not using adequate contraceptive methods
  • Pregnancy
  • Lactation
  • Any other condition that in the opinion of the investigator could interfere with theconduction of the study or interpretation of the study results

Study Design

Total Participants: 50
Study Start date:
February 17, 2022
Estimated Completion Date:
August 31, 2025

Study Description

In this randomized, double-blind, parallel, placebo-controlled trial we compare the effects of semaglutide 1.34 mg/ml vs. normal dieting by randomizing the patients with both T2DM and overweight/obesity (BMI ≥27) (n=50, aged ≥18 to < 65 years) to two groups: both groups participate in a similar lifestyle treatment to induce weight loss, but one group gets an add-on of semaglutide 1.34mg/ml while the other is treated with placebo. Additionally, a reference group of healthy normal weight non-diabetic individuals (BMI ≤ 25 kg/m2, n=25, aged ≥18 to < 65 years) are included as controls at the initiation of the study.

Connect with a study center

  • University of Helsinki

    Helsinki,
    Finland

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.